רבלימיד 15 מ"ג

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

LENALIDOMIDE 15 MG

Disponible desde:

NEOPHARM SCIENTIFIC LTD

Código ATC:

L04AX04

formulario farmacéutico:

CAPSULES

Vía de administración:

PER OS

Fabricado por:

CELGENE EUROPE LTD, UK

Grupo terapéutico:

LENALIDOMIDE

indicaciones terapéuticas:

1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Fecha de autorización:

2009-04-01